Granules India (GRANULES.NS) Stock Price

Granules India Price

NSE·CLOSED
858.40INR+0.85 (+0.10 %)
Market closed

Over the last 19 years Granules India grew revenue by 18.5% annually, reaching 44.82 B INR. Earnings per share have grown at 21.1% per year over the last 19 years. For Granules India, the net margin of 11.2% is down versus 17.0% a few years ago. At today's price the dividend yield works out to roughly 0.17%. The payout ratio is around 7% of earnings. The dividend has grown at 1.1% per year over the past 17 years. The consensus 12-month price target for Granules India is 644.64 INR, about 24.9% below where the stock trades today. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 87% above its 52-week low.

Granules India stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Granules India over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Granules India stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Granules India's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Granules India Stock Price History
DateGranules India Price
8/14/2026858.40 INR
8/13/2026857.55 INR
8/12/2026858.25 INR
8/10/2026855.15 INR
8/7/2026873.85 INR
8/6/2026838.65 INR
8/5/2026845.10 INR
8/4/2026829.50 INR
7/31/2026824.65 INR
7/30/2026844.05 INR
7/28/2026843.50 INR
7/24/2026833.55 INR
7/23/2026858.55 INR
7/22/2026853.80 INR
7/21/2026875.70 INR
7/20/2026876.10 INR
7/17/2026880.80 INR
7/16/2026903.25 INR
7/15/2026898.05 INR
7/14/2026895.10 INR
7/13/2026897.65 INR
7/10/2026889.85 INR
7/9/2026882.05 INR
7/8/2026859.55 INR
7/7/2026863.55 INR
7/6/2026854.20 INR
7/3/2026834.95 INR
7/2/2026825.70 INR
7/1/2026811.40 INR
6/30/2026813.25 INR
6/29/2026794.80 INR
6/25/2026764.20 INR
6/24/2026770.85 INR
6/23/2026788.00 INR
6/22/2026778.40 INR
6/19/2026776.05 INR
6/18/2026745.10 INR
6/17/2026756.70 INR
6/16/2026749.30 INR
6/15/2026753.80 INR
6/12/2026774.50 INR
6/11/2026772.30 INR
6/10/2026761.25 INR
6/9/2026765.05 INR
6/8/2026766.35 INR
6/5/2026788.45 INR
6/4/2026791.35 INR
6/3/2026793.80 INR
6/2/2026777.55 INR
6/1/2026778.15 INR
5/29/2026791.00 INR
5/27/2026782.30 INR
5/26/2026767.60 INR
5/25/2026756.65 INR
5/22/2026765.50 INR
5/21/2026763.00 INR
5/20/2026763.70 INR
5/19/2026766.45 INR
5/18/2026731.45 INR
5/15/2026736.20 INR
5/14/2026735.30 INR
5/13/2026728.35 INR
5/12/2026729.05 INR
5/11/2026755.60 INR
5/8/2026752.95 INR
5/7/2026743.50 INR
5/6/2026736.00 INR
5/5/2026711.80 INR
5/4/2026703.40 INR
5/1/2026699.70 INR
4/30/2026699.70 INR
4/29/2026704.55 INR
4/28/2026705.15 INR
4/27/2026694.90 INR
4/24/2026689.45 INR
4/23/2026686.95 INR
4/22/2026672.75 INR
4/21/2026667.75 INR
4/20/2026664.45 INR
4/17/2026655.70 INR
4/16/2026651.00 INR
4/15/2026652.65 INR
4/13/2026632.40 INR
4/10/2026631.95 INR
4/9/2026635.50 INR
4/8/2026644.30 INR
4/7/2026638.80 INR
4/6/2026644.00 INR
4/2/2026613.60 INR
4/1/2026625.80 INR
3/30/2026620.10 INR
3/27/2026624.35 INR
3/25/2026626.00 INR
3/24/2026604.00 INR
3/23/2026586.70 INR
3/20/2026590.70 INR
3/19/2026582.50 INR
3/18/2026587.20 INR
3/17/2026570.20 INR
3/16/2026565.00 INR
3/13/2026560.50 INR
3/12/2026585.00 INR
3/11/2026586.80 INR
3/10/2026582.90 INR
3/9/2026560.60 INR
3/6/2026578.00 INR
3/5/2026576.00 INR
2/26/2026586.35 INR
2/25/2026600.00 INR
2/23/2026599.25 INR
2/20/2026599.05 INR
2/19/2026575.00 INR
2/18/2026582.40 INR
2/17/2026568.50 INR
2/16/2026564.00 INR
2/13/2026559.70 INR
2/12/2026570.00 INR
2/11/2026579.00 INR
2/10/2026578.00 INR
2/9/2026569.00 INR
2/6/2026563.70 INR
2/5/2026578.60 INR
2/4/2026582.70 INR
2/3/2026571.00 INR
2/2/2026553.00 INR
1/30/2026572.00 INR
1/29/2026574.15 INR
1/28/2026564.90 INR
1/27/2026579.10 INR
1/23/2026565.00 INR
1/22/2026572.00 INR
1/21/2026538.05 INR
1/20/2026552.75 INR
1/19/2026574.00 INR
1/16/2026583.10 INR
1/14/2026597.85 INR
1/13/2026590.80 INR
1/12/2026594.85 INR
1/9/2026601.95 INR
1/8/2026607.35 INR
1/7/2026610.95 INR
1/6/2026610.15 INR
1/5/2026604.25 INR
1/2/2026615.00 INR
1/1/2026619.20 INR
12/31/2025600.95 INR
12/30/2025598.40 INR
12/29/2025603.15 INR
12/26/2025617.35 INR
12/24/2025612.50 INR
12/23/2025614.80 INR
12/22/2025600.75 INR
12/19/2025583.30 INR
12/18/2025581.95 INR
12/17/2025578.95 INR
12/16/2025575.00 INR
12/15/2025571.60 INR
12/12/2025574.00 INR
12/11/2025564.75 INR
12/10/2025554.85 INR
12/9/2025560.45 INR
12/8/2025543.95 INR
12/5/2025560.85 INR
12/4/2025566.40 INR
12/3/2025568.10 INR
12/2/2025570.20 INR
12/1/2025568.75 INR
11/28/2025558.50 INR
11/27/2025549.00 INR
11/26/2025547.00 INR
11/25/2025546.15 INR
11/24/2025532.85 INR
11/21/2025544.20 INR
11/20/2025549.00 INR
11/19/2025553.95 INR
11/18/2025560.50 INR
11/17/2025561.90 INR
11/14/2025548.20 INR
11/13/2025554.05 INR
11/12/2025542.95 INR
11/11/2025535.00 INR
11/10/2025550.15 INR
11/7/2025554.65 INR
11/6/2025551.90 INR
11/4/2025566.00 INR
11/3/2025576.10 INR
10/31/2025566.25 INR
10/30/2025574.35 INR
10/29/2025570.95 INR
10/28/2025570.00 INR
10/27/2025565.00 INR
10/24/2025561.95 INR
10/23/2025557.15 INR
10/21/2025570.05 INR
10/20/2025566.30 INR
10/17/2025569.55 INR
10/16/2025570.50 INR
10/15/2025568.00 INR
10/14/2025569.00 INR
10/13/2025564.00 INR
10/10/2025568.00 INR
10/9/2025566.00 INR
10/8/2025548.75 INR
10/7/2025555.90 INR
10/6/2025552.70 INR
10/3/2025560.00 INR
10/1/2025544.50 INR
9/30/2025517.00 INR
9/29/2025514.60 INR
9/26/2025515.90 INR
9/25/2025530.15 INR
9/24/2025531.50 INR
9/23/2025522.50 INR
9/22/2025527.05 INR
9/19/2025545.00 INR
9/18/2025544.80 INR
9/17/2025545.95 INR
9/16/2025539.00 INR
9/15/2025533.35 INR
9/12/2025533.25 INR
9/11/2025525.90 INR
9/10/2025522.80 INR
9/9/2025525.10 INR
9/8/2025518.85 INR
9/5/2025511.40 INR
9/4/2025510.10 INR
9/3/2025516.50 INR
9/2/2025507.80 INR
9/1/2025515.80 INR
8/29/2025492.25 INR
8/28/2025470.00 INR
8/26/2025469.50 INR
8/25/2025460.70 INR
8/22/2025458.50 INR
8/21/2025462.00 INR
8/20/2025461.35 INR
8/19/2025458.05 INR
8/18/2025461.00 INR
Access this data via the Eulerpool API
Get Free API Key

Granules India Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
37.65 B INR
5.75 B INR
4.13 B INR
Jan 1, 2023
45.12 B INR
7.38 B INR
5.17 B INR
Jan 1, 2024
45.06 B INR
6.53 B INR
4.05 B INR
Jan 1, 2025
44.82 B INR
7.25 B INR
5.02 B INR
Jan 1, 2026 (e)
52.98 B INR
8.37 B INR
5.58 B INR
Jan 1, 2027 (e)
62.62 B INR
9.89 B INR
7.95 B INR
Jan 1, 2028 (e)
72.20 B INR
11.41 B INR
9.90 B INR
Jan 1, 2029 (e)
84.08 B INR
13.28 B INR
11.53 B INR

Granules India Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 3:00 PM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
10.9612.9313.8314.3516.9222.7925.9932.3837.6545.1245.0644.8252.9862.6272.2084.08
43.3717.986.963.7917.8734.7214.0124.5916.2919.84-0.12-0.5518.2118.2015.3016.45
40.0340.8244.7950.0545.5544.1349.8855.7648.6045.5851.2057.5557.5557.5557.5557.55
4.395.286.197.187.7110.0612.9618.0518.3020.5623.0725.7930.4936.0441.5548.38
1.291.562.182.332.022.794.227.135.757.386.537.258.379.8911.4113.28
11.7512.0715.7416.2311.9612.2416.2322.0315.2716.3514.4916.1715.8015.8015.8015.80
0.750.911.231.651.332.363.355.504.135.174.055.025.587.959.9011.53
130.6720.8835.3133.74-19.3978.2841.8863.83-24.8825.12-21.5323.7411.2942.3924.5416.46
3.500.651.071.001.001.001.001.501.003.001.501.501.501.631.76–
75.00-81.4364.62-6.54–––50.00-33.33200.00-50.00––8.677.98–
206.00206.00211.00220.00242.00255.00255.00250.00249.00245.74242.35242.50242.50242.50242.50242.50
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Granules India generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Granules India retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Granules India's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Granules India has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Granules India's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Granules India stock margins

The Granules India margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Granules India. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Granules India.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
55.76 %
22.03 %
16.97 %
Jan 1, 2022
48.60 %
15.27 %
10.96 %
Jan 1, 2023
45.58 %
16.35 %
11.45 %
Jan 1, 2024
51.20 %
14.49 %
8.99 %
Jan 1, 2025
57.55 %
16.17 %
11.19 %
Jan 1, 2026 (e)
57.55 %
15.80 %
10.54 %
Jan 1, 2027 (e)
57.55 %
15.80 %
12.69 %
Jan 1, 2028 (e)
57.55 %
15.80 %
13.71 %

Granules India Stock Revenue, EBIT, Earnings per Share

The Granules India earnings per share therefore indicates how much revenue Granules India has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
129.50 INR
28.52 INR
21.98 INR
Jan 1, 2022
151.20 INR
23.09 INR
16.58 INR
Jan 1, 2023
183.61 INR
30.02 INR
21.02 INR
Jan 1, 2024
185.94 INR
26.94 INR
16.72 INR
Jan 1, 2025
184.81 INR
29.88 INR
20.68 INR
Jan 1, 2026 (e)
218.32 INR
34.51 INR
23.00 INR
Jan 1, 2027 (e)
258.04 INR
40.79 INR
32.75 INR
Jan 1, 2028 (e)
297.52 INR
47.03 INR
40.79 INR

Granules India business model & stock analysis

Granules India Ltd is a registered company in Hyderabad, India, specializing in the manufacturing of pharmaceutical active ingredients and formulations, product development, biotechnology research, and diagnostics. The company was established in 1984 and has become one of the leading suppliers of pharmaceutical active ingredients. The origins of Granules India Ltd began as a small company with only a few employees. In 1991, the company started production of Allantoin, a cosmetic active ingredient. Over the years, the company steadily grew and expanded its production capacities. In 1995, Granules India Ltd began manufacturing pharmaceutical active ingredients as part of its business. In the late 90s, the company expanded into other countries to distribute its products worldwide. Today, the main markets for Granules India Ltd are India, North America, Europe, and Asia. The company also has distribution offices in the USA, Europe, and Asia. Granules India Ltd has divided its business model into three main sectors: 1. Pharmaceutical Active Ingredients (APIs) - Granules India Ltd specializes in the manufacturing of pharmaceutical active ingredients used in drug production. The company produces a wide range of APIs, including Paracetamol, Ibuprofen, Metformin, and more. 2. Formulations - Granules India Ltd also produces various pharmaceutical formulations such as tablets, capsules, suspensions, and more. The company is able to develop and manufacture customized formulations according to customer requirements. 3. Biologics - In recent years, the company has also invested in biotechnology research, particularly in the development and manufacturing processes of biologics such as antibody drugs. The field of diagnostics is also covered. Granules India Ltd has established a strong position as a manufacturer of pharmaceutical active ingredients in recent years. The company supplies many of the major pharmaceutical companies worldwide. It has six production facilities in India that manufacture pharmaceutical active ingredients and formulations. The company also supplies to other manufacturers to support their production processes. In terms of products, Granules India Ltd offers a wide range of pharmaceutical active ingredients and formulations, all manufactured to the highest quality and in compliance with international standards. Some of the company's most well-known products are Paracetamol, Ibuprofen, Metformin, and Tramadol, used in pain management. The wide range of formulations includes tablets, capsules, suspensions, and more, used in various therapy areas such as cardiology, oncology, neurology, and infectious diseases. Overall, Granules India Ltd has achieved a leading position in the market for pharmaceutical active ingredients and formulations. The company has invested in research and development in recent years to expand its product range and provide customized solutions. Granules India Ltd remains committed to meeting the high standards in the pharmaceutical industry and developing innovative products to meet the needs of its customers.

Granules India SWOT Analysis

Strengths

Granules India Ltd has a strong presence in the pharmaceutical industry.

The company has a diverse portfolio of products.

Granules India Ltd has established strong relationships with clients, suppliers, and distributors.

Weaknesses

The company may face challenges in maintaining consistent quality across its product range.

Granules India Ltd relies heavily on third-party suppliers for raw materials, which poses a risk to its supply chain.

Opportunities

The growing demand for generic drugs presents a significant opportunity for Granules India Ltd to expand its market share.

Expansion into new geographic markets can help the company diversify its revenue streams.

Increasing investments in research and development can enable Granules India Ltd to develop innovative products.

Threats

Intense competition within the pharmaceutical industry may impact Granules India Ltd's market position.

Changes in government regulations and policies can pose a threat to the company's operations.

Economic downturns or fluctuations in currency exchange rates can affect Granules India Ltd's financial performance.

Granules India Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Granules India historical P/E ratio, EBIT multiple, and P/S ratio

Granules India annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Granules India shares outstanding

The number of shares of Granules India was 242.5 M in 2025. This indicates how many shares Granules India is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
250.00 M Stocks
Jan 1, 2022
249.00 M Stocks
Jan 1, 2023
245.74 M Stocks
Jan 1, 2024
242.35 M Stocks
Jan 1, 2025
242.50 M Stocks
Jan 1, 2026 (e)
242.50 M Stocks
Jan 1, 2027 (e)
242.50 M Stocks
Jan 1, 2028 (e)
242.50 M Stocks

Granules India stock splits

In Granules India's history, there have been no stock splits.

Granules India Dividend History

18 years of dividend payments

YearAnnual DividendYoY ChangePayments
20251.50INR 0.0%1×
Jul 31, 20251.50INR 0.0%1/1
20241.50INR 0.0%1×
20231.50INR↑ 50.0%1×
20221.00INR↓ 33.3%2×
20211.50INR↑ 50.0%4×
20201.00INR 0.0%4×
20191.00INR 0.0%4×
20181.00INR 0.0%4×
20171.00INR↑ 33.3%4×
20160.75INR↑ 15.4%4×

Granules India dividend history and estimates

In 2025, Granules India paid a dividend amounting to 1.50 INR. Dividend means that Granules India distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
1.50 INR
0.00 INR
Jan 1, 2022
1.00 INR
0.00 INR
Jan 1, 2023 (e)
1.50 INR
1.50 INR
Jan 1, 2024
1.50 INR
0.00 INR
Jan 1, 2025
1.50 INR
0.00 INR
Jan 1, 2026
1.50 INR
0.00 INR
Jan 1, 2027 (e)
0.00 INR
1.63 INR
Jan 1, 2028 (e)
0.00 INR
1.76 INR

Granules India dividend payout ratio

In 2025, Granules India had a payout ratio of 7.25%. The payout ratio indicates the percentage of the company's profits that Granules India distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
6.82 %
Jan 1, 2022
6.04 %
Jan 1, 2023
7.14 %
Jan 1, 2024
8.97 %
Jan 1, 2025
7.25 %
Jan 1, 2026 (e)
6.52 %
Jan 1, 2027 (e)
4.97 %
Jan 1, 2028 (e)
4.33 %

Current Granules India forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.35 %
Buy
84.62 % (11)
Hold
15.38 % (2)
Sell
0.00 % (0)
12M Price Target
644.64
Last Price
858.40
Currency
INR
12M Return Potential
-24.90 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Granules India stock

64/100
70
Environment
61
Social
62
Governance
E

Environment

20
Scope 1 - Direct Emissions56,254
Scope 2 - Indirect emissions from purchased energy31,632
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions87,886
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees7.789
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Granules India shareholder structure

% Name
31.64755%
Chigurupati (Krishna Prasad)
Chigurupati (Krishna Prasad)
5.33217%
Life Insurance Corporation of India
Life Insurance Corporation of India
3.80795%
Chigurupati (Uma Devi)
Chigurupati (Uma Devi)
3.01626%
SBI Life Insurance Co., Ltd.
SBI Life Insurance Co., Ltd.
2.59711%
Axis Asset Management Company Limited
Axis Asset Management Company Limited
2.53399%
Aditya Birla Sun Life AMC Limited
Aditya Birla Sun Life AMC Limited

Granules India Beneficial Ownership Filings (SEC 13D/G)

Free Float
60.7%
Float Shares
-
Shares Outstanding
-

Granules India Executives and Management Board

21 members · avg. age 62 · 19 % women

KC

Dr. Krishna Chigurupati (69)

Executive Chairman of the Board, Managing Director · since 2014

316.37 M INR

Management

KR

Dr. Kandiraju Rao

Chief Executive Officer, Joint Managing Director, Executive Director · since 2022

96.55 M INR
CT

Ms. Chaitanya Tummala

Compliance Officer, Company Secretary

7.89 M INR
MS

Mr. Mukesh Surana

Chief Financial Officer

–
SK

Mr. Sanjay Kumar

President and Chief Strategy and Sustainability Officer · since 2024

–
RR

Mr. Ramraj Rangarajulu

President and Head - Formulations Operations

–
AD

Mr. Atul Dhavle

Chief Human Resource Officer

–

Board of Directors

HC

Mr. Harsha Chigurupati (40)

Non-Independent Executive Director · since 2010

31.64 M INR
UC

Mrs. Uma Chigurupati (64)

Non-Independent Executive Director · since 2012

31.64 M INR
AS

Mr. Arun Sawhney

Non-Executive Independent Director

4.16 M INR
KR

Mr. Kolli Rao (70)

Non-Executive Non-Independent Director

3.83 M INR
SC

Dr. Saumen Chakraborty (62)

Non-Executive Independent Director

3.70 M INR
SP

Mrs. Sucharita Palepu (57)

Non-Executive Independent Director

3.36 M INR

Frequently asked questions about Granules India

Granules India Ltd operates under a business model that focuses on pharmaceutical manufacturing. The company specializes in the production and distribution of active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). With an extensive portfolio of products, Granules India Ltd caters to both domestic and international markets. By leveraging their strong research and development capabilities, the company ensures the highest quality standards in drug manufacturing. Granules India Ltd's commitment to innovation and customer-centric approach has established them as a leading player in the pharmaceutical industry.

Granules India Ltd is primarily active in the pharmaceutical industry. With its focus on manufacturing and exporting pharmaceutical products, the company plays a crucial role in the healthcare sector. Granules India Ltd has established itself as a leading player in the global pharmaceutical market, providing high-quality active pharmaceutical ingredients (APIs), intermediates, and finished dosages to customers worldwide. The company's commitment to innovation, quality, and customer satisfaction has contributed to its success and growth in the highly competitive pharmaceutical industry. Granules India Ltd continuously strives to meet the healthcare needs of patients by providing affordable and effective medicines.

The main competitors of Granules India Ltd in the market include Aurobindo Pharma Ltd, Divis Laboratories Ltd, and Dr. Reddy's Laboratories Ltd.

Granules India Ltd is a leading pharmaceutical company that specializes in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). Established in 1984, Granules India Ltd has grown exponentially over the years and is now recognized as one of India's largest vertically integrated pharmaceutical manufacturers. With a strong focus on research and development, Granules India Ltd has successfully developed and commercialized numerous products for various therapeutic segments. The company's commitment to quality, innovation, and customer satisfaction has positioned it as a trusted global player in the pharmaceutical industry. Granules India Ltd continues to expand its product portfolio and strengthen its presence in both domestic and international markets.

Granules India Ltd has achieved several significant milestones in its journey. The company has successfully established itself as a leading manufacturer of pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs). With a focus on innovation and quality, Granules India Ltd has received multiple certifications, including EU GMP and US FDA approvals for its manufacturing units. The company has also expanded its presence globally, with a strong customer base across various countries. Additionally, Granules India Ltd has consistently shown robust financial performance, with steady revenue growth and improved profitability. These achievements highlight the company's commitment to excellence and make it a trusted name in the pharmaceutical industry.

Granules India Ltd is primarily present in India, as it is an Indian pharmaceutical company. It has established a strong presence in the domestic market and has been serving the healthcare needs of millions of people in the country. With its state-of-the-art manufacturing facilities located across various regions in India, Granules India Ltd has successfully catered to the growing demand for high-quality pharmaceutical products. Additionally, the company has also expanded its global footprint and has a significant presence in several countries worldwide, including the United States, Europe, and Asia, through its diverse customer base and strategic partnerships.

Granules India Ltd represents values of integrity, quality, and patient-centricity. With a corporate philosophy focused on innovation and customer satisfaction, the company strives to provide cost-effective and high-quality pharmaceutical products. Granules India Ltd emphasizes on continuous improvement, ethical business practices, and delivering value to all stakeholders. The company's commitment to research, development, and regulatory compliance highlights its dedication to providing safe and effective healthcare solutions. Through its customer-centric approach and consistent growth, Granules India Ltd has established itself as a leading player in the pharmaceutical industry.

Analysts currently set an average price target of 643.62 INR for the Granules India stock (median: 644.64 INR), implying -25.0 % versus the latest price. The consensus is based on 13 analyst ratings.

Granules India Analyst Price Targets 2026

13 analysts currently rate the Granules India stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Granules India to generate revenue of 52.98 B INR and earnings per share of 23.02 INR.

Granules India Analyst Price Targets 2026

Converted at the current exchange rate, the Granules India share trades at 7.77 EUR (858.40 INR).

Granules India Ltd is a leading company in the pharmaceutical active ingredient and formulation industry, headquartered in Hyderabad, India. It started as a small company in 1984 and has grown into a multinational company operating in over 60 countries. The business areas of Granules India include pharmaceutical active ingredients, dosage forms, research and development, as well as equipment and supplies. The company is a major player in the manufacturing of generic drugs, which provide a cost-effective alternative to more expensive patented medications. Pharmaceutical active ingredients: Granules India produces a wide range of pharmaceutical active ingredients used in various medical applications, including pain management, metabolic disorders, cardiovascular and infectious diseases. The company has a strong expertise in manufacturing active ingredients for novel drugs and offers a wide range of products in different therapy areas. Dosage forms: The company also produces a variety of dosage forms such as tablets, capsules, granules, and powders, which allow for the delivery of active ingredients in the desired quantity and dosage to the patient. Granules India works closely with its customers to develop customized solutions for their specific requirements. Research and development: Granules India maintains an extensive research and development department specializing in the development and manufacturing of novel active ingredients and formulations. The company is committed to seeking new technologies and techniques to produce better pharmaceutical products that are more effective and safer. Equipment and supplies: Granules India also has a department for equipment and supplies that support the manufacturing of pharmaceutical products. They manufacture machines and equipment used by other pharmaceutical companies to produce their products. They also offer specialized services such as installation, maintenance, and repair of these equipment. Granules India is also a key player in the development of biosimilars approved by the Food and Drug Administration (FDA). The company also develops and manufactures topical medications such as ointments, gels, and creams, which treat skin issues and infections. Overall, Granules India has an impressive business model and offers a wide range of pharmaceutical products and services. The company has focused on quality, collaboration, and innovation, and is able to provide tailored solutions to its customers' specific needs.

The expected revenue of Granules India is 52.98 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Granules India is 5.58 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Granules India is currently 37.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Granules India stock.

The price-to-sales ratio (P/S) of Granules India is currently 3.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Granules India stock.

The Eulerpool Quality Score for Granules India is 8/10.

The ISIN of Granules India is INE101D01020. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Granules India is GRANULES.NS. The ticker symbol is used to trade Granules India shares on the stock exchange.

Over the past 12 months, Granules India paid a dividend of 1.50 INR . This corresponds to a dividend yield of about 0.17 %. For the coming 12 months, Granules India is expected to pay a dividend of 1.63 INR.

The current dividend yield of Granules India is 0.17 %.

Granules India pays a dividend, distributed in the months of , , , .

Granules India paid dividends every year for the past 18 years.

For the upcoming 12 months, dividends amounting to 1.63 INR are expected. This corresponds to a dividend yield of 0.19 %.

Granules India is assigned to the 'Health' sector.

To receive the latest dividend of Granules India from amounting to 1.5 INR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Granules India distributed 1.5 INR as dividends.

The dividends of Granules India are distributed in INR.

All fundamentals and in-depth analysis of Granules India

Our stock analysis for Granules India stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Granules India. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Granules India Stock
Granules India Revenue→
Granules India Stock
Granules India Net Income→
Granules India Stock
Granules India P/E→
Granules India Stock
Granules India P/S→
Granules India Stock
Granules India EBIT→
Granules India Stock
Granules India Dividend→
Granules India Stock
Granules India Directors Dealings→
Granules India Stock
Granules India Stocks→
Granules India Stock
Granules India Market capitalization→
Granules India Stock
Granules India Debt→
Granules India Stock
Granules India Liabilities→
Granules India Stock
Granules India Equity→
Granules India Stock
Granules India AAQS→
Granules India Stock
Granules India Employees→
Granules India Stock
Granules India ROE→
Granules India Stock
Granules India ROA→
Granules India Stock
Granules India ROCE→
Granules India Stock
Granules India News→
Granules India Stock
Granules India Analyst Price Targets→

Health Stocks

Grapefruit USAGrand Brilliance Group HoldingsGreat Elm GroupGrailGreen Cross HoldingsgraceNT AG in LiquidationGreen Cross Medical ScienceGrace Therapeutics,Green LifeScience CoGrace BreedingGreenrise Global BrandsGPT HealthcareAll Stocks A–Z →